Jason Gerberry Analyst PerformanceEquity Research at Bank of AmericaJason Gerberry is a stock analyst at Bank of America in the healthcare sector, covering 32 publicly traded companies. Over the past year, Jason Gerberry has issued 32 stock ratings, including buy, hold, and sell recommendations. While full access to Jason Gerberry's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason Gerberry's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings135 Last 11 YearsBuy Recommendations69.17% 92 Buy RatingsCompanies Covered32 Unique Companies Ratings Distribution133RatingsDistribution of strong buy, buy, hold, and sell ratings by Jason Gerberry.RatingPercentageCount Strong Buy0.0%0 ratings Buy69.2%92 ratings Hold23.3%31 ratings Sell7.5%10 ratingsOut of 133 total stock ratings issued by Jason Gerberry at Bank of America, the majority (69.2%) have been Buy recommendations, followed by 23.3% Hold and 7.5% Sell.Best & Worst CallsBest Call0000.0%LQDAJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BLPHJul 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ75.0% of companies on NASDAQ24 companiesNYSE25.0% of companies on NYSE8 companiesJason Gerberry, an analyst at Bank of America, currently covers 32 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare32 companies100.0%Jason Gerberry of Bank of America specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentagePHARMACEUTICALS21 companies65.6%BIOTECHNOLOGY11 companies34.4% Jason Gerberry's Ratings History at Bank of America Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsPFEPfizer7/10/2026Lower Price Target$24.25$26.00Neutral$0.0000.00% ROILLYEli Lilly and Company7/10/2026Boost Price Target$1,183.80$1,334.00Buy$0.0000.00% ROIALKSAlkermes6/29/2026Reiterated Rating$55.08Underperform$0.0000.00% ROILQDALiquidia6/29/2026Reiterated Rating$78.17$79.00Neutral$0.0000.00% ROIAMPHAmphastar Pharmaceuticals6/29/2026Reiterated Rating$21.78$20.00Underperform$0.0000.00% ROIBHVNBiohaven6/29/2026Reiterated Rating$15.79$11.00Underperform$0.0000.00% ROIJAZZJazz Pharmaceuticals6/10/2026Boost Price Target$229.19$307.00Buy$0.0000.00% ROILLYEli Lilly and Company5/26/2026Boost Price Target$1,066.59$1,251.00Buy$0.0000.00% ROIIMVTImmunovant5/21/2026Boost Price Target$35.56$43.00Buy$0.0000.00% ROILLYEli Lilly and Company5/1/2026Lower Price Target$965.19$1,133.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. TEVATeva Pharmaceutical Industries4/9/2026Boost Price Target$30.77$42.00Buy$0.0000.00% ROIPFEPfizer4/9/2026Lower Price Target$27.39$26.00Neutral$0.0000.00% ROIIONSIonis Pharmaceuticals4/9/2026Boost Price Target$76.12$111.00Buy$0.0000.00% ROIALKSAlkermes4/9/2026Boost Price Target$34.90$36.00Neutral$0.0000.00% ROILLYEli Lilly and Company4/2/2026Boost Price Target$955.45$1,294.00Buy$0.0000.00% ROILENZLENZ Therapeutics3/25/2026Lower Price Target$9.03$29.00Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals2/25/2026Boost Price Target$173.83$275.00Buy$0.0000.00% ROIHRMYHarmony Biosciences2/25/2026Lower Price Target$28.19$28.00Underperform$0.0000.00% ROIALKSAlkermes2/20/2026Boost Price Target$32.00$34.00Neutral$0.0000.00% ROIPFEPfizer12/15/2025Lower Price Target$25.86$28.00Neutral$0.0000.00% ROIARWRArrowhead Pharmaceuticals12/9/2025Boost Price Target$69.57$81.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals12/9/2025Boost Price Target$79.56$97.00Buy$0.0000.00% ROITEVATeva Pharmaceutical Industries12/9/2025Boost Price Target$28.60$32.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals12/1/2025Boost Price Target$55.43$62.00Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals11/18/2025Boost Price Target$170.09$247.00Buy$0.0000.00% ROIOCSOculis11/13/2025Lower Price Target$19.25$29.00Buy$0.0000.00% ROIBHVNBiohaven11/5/2025Downgrade$8.10$10.00Neutral$0.0000.00% ROIIONSIonis Pharmaceuticals9/23/2025Boost Price Target$61.36$83.00Buy$0.0000.00% ROIAMPHAmphastar Pharmaceuticals8/26/2025Boost Price Target$30.54$32.00Neutral$0.0000.00% ROIIMVTImmunovant8/12/2025Lower Price Target$14.76$30.00Buy$0.0000.00% ROIBHVNBiohaven8/12/2025Lower Price Target$13.42$49.00Buy$0.0000.00% ROIAXSMAxsome Therapeutics8/5/2025Boost Price Target$102.86$176.00Buy$0.0000.00% ROIPROKProKidney6/30/2025Downgrade$0.67$1.00Underperform$0.0000.00% ROILQDALiquidia6/11/2025Lower Price Target$14.34$23.00Buy$00.0000.00% ROIEXELExelixis6/5/2025Boost Price Target$42.55$46.00Neutral$00.0000.00% ROITEVATeva Pharmaceutical Industries5/8/2025Boost Price Target$18.08$22.00Buy$00.0000.00% ROIPCVXVaxcyte4/1/2025Lower Price Target$36.81$137.00Buy$00.0000.00% ROIIMVTImmunovant3/20/2025Lower Price Target$18.88$33.00Buy$00.0000.00% ROITEVATeva Pharmaceutical Industries3/6/2025Lower Price Target$15.59$20.00Buy$00.0000.00% ROIVTRSViatris2/28/2025Lower Price Target$9.53$10.00Underperform$00.0000.00% ROITrump’s $250 Bill – See Immediately (Ad)Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in modern history - larger than Paul Tudor Jones' Black Monday bet and Michael Burry's $700 million Big Short. While most investors chase AI stocks, insiders including Ray Dalio and Tudor Jones have quietly repositioned. The last comparable shock sent certain stocks up 2,464%, 2,778%, and even 13,000% - turning a $10,000 stake into over $1.3 million. Dr. Eifrig has identified one stock at the center of this story and released a free broadcast to help investors act before the window closes.Watch the free broadcast now and learn where to position your moneyAXSMAxsome Therapeutics2/11/2025Boost Price Target$133.41$167.00Buy$000.0000.00% ROIIMVTImmunovant1/15/2025Lower Price Target$22.88$45.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupUBS GroupThe Goldman Sachs GroupWeiss RatingsCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.TD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
